Canagliflozin and Renal Outcomes in Type 2 Diabetes and NephropathyVlado Perkovic, Kenneth W. Mahaffey, Tom Greene et al.|New England Journal of Medicine|2019Cited by 6k
Global kidney health 2017 and beyond: a roadmap for closing gaps in care, research, and policyAdeera Levin, Robert G. Nelson, Chih-Wei Yang et al.|The Lancet|2017Cited by 923
Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trialHiddo J.L. Heerspink, Chris Vercammen, Hans‐Henrik Parving et al.|The Lancet|2019Cited by 609
Iron management in chronic kidney disease: conclusions from a “Kidney Disease: Improving Global Outcomes” (KDIGO) Controversies ConferenceIain C. Macdougall, Yusuke Tsukamoto, Elena Zakharova et al.|Kidney International|2016Cited by 474
RIPK3 blockade attenuates tubulointerstitial fibrosis in a mouse model of diabetic nephropathyYing Shi, Carol A. Pollock|Scientific Reports|2020Cited by 43